Product Description
Mechanisms of Action: Histamine Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Belgium | Brazil | Chile | China | Colombia | Czech | Dominican Republic | Ecuador | Egypt | Estonia | Finland | Greece | Hong Kong | Hungary | India | Indonesia | Italy | Korea | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Spain | Thailand | Turkey | Ukraine | United Arab Emirates | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Dompe
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Czech Republic
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Dyspnea
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
INFURO_2023 | P2 |
Unknown Status |
Dyspnea |
2026-01-01 |